Latest findings on the prevention of cardiovascular events - Focus on the AT 1 receptor

Issei Komuro,Shinichiro Miura,Yunzeng Zou
2004-01-01
Abstract:Activation of cells via the angiotensin II typel receptor (AT 1) is closely related to the development of cardiovascular events. AT 1 activation, which leads to various effects, was thought to be induced by only binding of the ligand angiotensin II (AngII) to AT 1, but Zou et al. discovered a novel mechanism of its activation by stretch without the involvement of AngII. Miura et al. have reported findings suggesting that activation of cells via the AT 1 can be partially controlled using AngII analogs. These reports suggest that a stimulus causing conformational changes of the receptor is the most important factor in AT 1 activation. AT 1 blockers (ARB) are attracting attention as drugs for the prevention of cardiovascular events. However, the effects of ARB vary and they can be classified into drugs that only inhibit the binding of AngII to the AT 1 (competitive antagonists) and those that also inhibit the activation by stretch (inverse agonists). Because inverse agonists also inhibit basal AT 1 activity, such drugs should have more potent preventive effects on cardiovascular events than competitive antagonists.
What problem does this paper attempt to address?